Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1901 Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: MULLER N

Authors: Muller N, Zappa M, Hammel P, De Mestier L, Laurent L,

Keywords: portal hypertension,

#1900 Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors

Introduction: Well-differentiated G1/G2 pancreatic NET (pNET) may evolve towards well-differentiated G3 pNET or carcinoma (pNEC)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Olivia H

Authors: Hentic O, Cros J, Rebours V, Zappa M, Muller N,

Keywords: dedifferentiation, new biopsy,

#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours

Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Hentic O

Authors: Hentic O, Cros J, Zappa M, Rebours V, Muller N,

Keywords: MGMT, Streptozotocin, PFS ,

#842 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki-67 Index Predict Response to Temozolomide in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)

Introduction: Temozolomide (TEM) showed encouraging results in WDPNET. Decreased MGMT expression and methylation of its promoter seems to correlate with better outcome in TEM-treated glioblastomas.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Cros J

Authors: Cros J, Hentic O, Rebours V, Zappa M, Maire F,

Keywords: MGMT, pancreatic NET, temozolomide,

#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)

Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hentic O, Cros J, Rebours V, Zappa M, Maire F,

Keywords: neuroendocrine tumor, treatment, temozolomide, MGMT,